{
    "clinical_study": {
        "@rank": "112784", 
        "acronym": "ACTION", 
        "arm_group": {
            "arm_group_label": "RA patients treated with Abatacept", 
            "description": "RA patients are treated with Abatacept IV according Summary of Product Characteristics (SmPC) in Europe and Product Monograph in Canada"
        }, 
        "biospec_descr": {
            "textblock": "Whole blood (Spanish sub study only)"
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "The purpose of this study is to estimate the retention rate of Abatacept over 24 months in\n      routine clinical practice in every participating country depending on the treatment line."
        }, 
        "brief_title": "Long Term Experience With Abatacept in Routine Clinical Practice", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Time Perspective: Other: Collection of the baseline data collected at Abatacept IV\n      initiation, prospectively or retrospectively within maximum 3 months following the first\n      administration. Other assessments are collected during the follow up period (maximum of 2\n      years by patient)\n\n      Biospecimen Retention: None Retained excepted for a local sub study (in Spain) where sample\n      with DNA was retained"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Male or Female subjects of more than 18 years old\n\n          -  Patients with a diagnosis of established moderate to severe active RA (as per the\n             American College of Rheumatology revised criteria, 1987), who at their physician's\n             discretion are treated with Abatacept according to the SmPC in Europe and the Product\n             Monograph in Canada (initiating or already on treatment for maximum 3 months) and for\n             whom baseline characteristics are available\n\n        Exclusion Criteria:\n\n          -  Patients who are currently included in any interventional clinical trial in RA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Crohn's Disease"
            }
        }, 
        "enrollment": {
            "#text": "1255", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109666", 
            "org_study_id": "IM101-151"
        }, 
        "intervention": {
            "arm_group_label": "RA patients treated with Abatacept", 
            "intervention_name": "Abatacept", 
            "intervention_type": "Drug", 
            "other_name": "Orencia"
        }, 
        "intervention_browse": {
            "mesh_term": "Abatacept"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. John's", 
                        "country": "Canada", 
                        "state": "Newfoundland and Labrador", 
                        "zip": "A1B3E1"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague 2", 
                        "country": "Czech Republic", 
                        "zip": "128 50"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Holbaek", 
                        "country": "Denmark", 
                        "zip": "4300"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "64120"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Crete", 
                        "country": "Greece", 
                        "zip": "71 201"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy", 
                        "zip": "53100"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1056 AB"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0012"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41071"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0013"
                }, 
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "4055"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "Canada", 
                "Czech Republic", 
                "Denmark", 
                "France", 
                "Germany", 
                "Greece", 
                "Italy", 
                "Netherlands", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Long Term Experience With Abatacept in Routine Clinical Practice", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Ministry of Health", 
                "Greece: National Organization of Medicines", 
                "Germany: Paul-Ehrlich-Institut"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Retention rate of Rheumatoid arthritis (RA) patients treated with Abatacept in routine clinical practice", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109666"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Major determinants including prior RA treatment experience with biologics and clinical outcomes, such as Disease Activity Score 28 (DAS28), Health Assessment Questionnaire-Disability Index (HAQ-DI), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and their derived criteria", 
                "measure": "Major determinants of treatment discontinuation of RA patients treated with Abatacept", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Distribution of time-to-discontinuation of Abatacept therapy for each major determinant of treatment discontinuation, overall and depending on the treatment line", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Association of prior RA treatment experience and clinical outcomes during the treatment course with patient reported outcomes (Patient satisfaction, Pain, Patient's Global Assessment)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Summary of treatment experience and outcomes after switching to a biologic or conventional Disease Modifying Anti-Rheumatic Drugs (DMARD) for patients who discontinue Abatacept therapy", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2008", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}